<a href="https://www.fiercebiotech.com/cro/asco-ryght-ai-team-breast-cancer-trial-site-selection" hreflang="en">ASCO, Ryght AI team up for breast cancer trial site selection</a>
The American Society of Clinical Oncology (ASCO) and Ryght AI are collaborating to enhance site selection for a clinical trial on CDK4/6 inhibitors in metastatic breast cancer, using Ryght AI's platform to streamline the process and improve enrollment. The study, which focuses on older adults often underrepresented in trials, aims to determine optimal dosing strategies to improve treatment outcomes.
The collaboration between ASCO and Ryght AI using the AI Site Twin platform to optimize clinical trial site selection for metastatic breast cancer highlights a significant advance in accelerating trial timelines and improving patient outcomes. For professionals in healthtech and AI drug discovery, this presents a compelling model for leveraging AI to enhance trial efficiency and site suitability, potentially setting a precedent for future oncology studies and other therapeutic areas.